ACR 2021

New treatment alternative in GCA: promising secukinumab data

Pulmonary involvement and possible therapy concepts in RA

No need for methotrexate in ustekinumab treatment in PsA

axPsA is axSpA is not...!?

IL-17 pathway important for pain in PsA

ARIAA: prevention study or very early treatment of RA?

Dear Doctor: JAKi risk factors and safety profile - is there a class-effect?

Should we use ultra-low-dose rituximab during the pandemic?

Discordance between patients and physicians in RA

Nausea & alopecia with MTX in RA

Statins reduce cardiovascular risk and​ mortality - with a slight increase in type 2 diabetes risk

Cardiovascular disease in RA

We need predictors of response for RA treatment

Long awaited - MACE data from ORAL surveillance

Tofacitinib is associated with a slightly increased risk of cancer

Abatacept may reduce subclinical inflammation in RA-at risk patients

Cycling JAKi compared to switching to biologic DMARD in patients with RA

Désaccords patient/Médecin : se comprendre pour plus d'efficacité

Abatacept reduce la inflamación subclínica en pacientes con artralgia con riesgo de progresión a artritis reumatoide

Quels marqueurs de réponse aux traitements dans la vraie vie ?

Skifte mellom JAK hemmere sammenliknet med skifte til biologisk DMARD hos pasienter med RA

Quels effets indésirables peuvent être associés à la prise de MTX ?

Tofacitinid se asocia con un ligero incremento del riesgo de cáncer​

Las estatinas reducen el riesgo cardiovascular y la mortalidad, con un ligero aumento en el riesgo de diabetes tipo 2

Lange erwartet - MACE-Daten zur ORAL Surveillance

Comparison of composit indices for disease activity in PsA patients

Joint effusions and enthesitis after physical exertion

Axial PsA MRI data

Guselkumab in axial symptoms

No need for MTX in ustekinumab-treated patients

Secukinumab vs TNF-α blockers in enthesitis

Guselkumab: the better ustekinumab?!

Anemia is an issue in PsA - proper treatment possible!

Pain differs: Superior effect of IL-17-inhibition vs. TNF in PsA patients with uncontrolled inflammation

Upadacitinib in PsA

Osteoporosis in PsA

Tildrakizumab in PsA

PET/CT in diagnosis for PsA

Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events

Prediction of psoriatic arthritis in patients with psoriasis using DNA methylation profiles

Tildrakizumab bei PsA

Osteoporose bei PsA

Schmerz ist nicht gleich Schmerz: Unterschied von IL-17- und TNF-Inhibition

Previsione di sviluppo di artrite psoriasica in pazienti con psoriasi utilizzando profili di metilazione del DNA

Guselkumab: das bessere Ustekinumab?!

Guselkumab bei axialer Symptomatik

Studio di confronto tra i vari indici compositi per la valutazione di attività di malattia nell'Artrite Psoriasica

Datos de RM en APs axial

Anämie bei PsA ist ein Thema - effektive Therapie möglich!

Associazione di livelli di PCR e uso di FANS con gli eventi cardiovascolari

PET-CT zur Quantifizierung der Entzündung

Secukinumab vs TNF-α Blocker bei Enthesitis

Upadacitinib bei PsA

Gelenkergüsse und Enthesitis nach körperlicher Belastung

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

Self-monitoring of disease activity with a smartphone app is feasible in routine clinical management

JAK inhibitors - new kids on the block

Dose tapering of TNF inhibitors in axSpA

Axial PsA MRI data

l’auto-monitoraggio di malattia è fattibile nella gestione clinica di routine nei pazienti con Spondiloartrite assiale

Optimización de iTNF en EspAax

Inhibidores JAK: nuevas dianas en EspAax

Datos de RM en APs axial

Not yet a new standard: belimumab + rituximab

JAKi baricitinib successfully mastered phase II study

Kombination Belimumab und Rituximab noch kein neuer Standard

JAK-Inhibitor Baricitinib in Phase II erfolgreich

Secukinumab in giant cell arteritis

A new therapeutic approach for giant cell arteritis?

Baricitinib in relapsing giant cell arteritis

PET as a predictor of vascular damage in large-vessel vasculits

Secukinumab nell'arterite a cellule giganti

Il ruolo della PET nel predire il danno vascolare nelle vasculiti dei grandi vasi

Neuer Therapieansatz für die Riesenzellarteriitis?

Baricitinib nell'arterite a cellule giganti recidivante

Anticytokine antibodies causing severe microbacterial infection

Analysis of COVID-19 infection among vaccinated patients with rheumatic disease

Vaccination against Delta variant worse in patients treated with TNF-alpha blocker

TNF blockers reduce the antibody response to RNA vaccination

Should we use ultra-low-dose rituximab during the pandemic?

Breakthrough infections after SARS-CoV2-vaccination - global registry

Booster with which one if there is no seroconversion?

Breakthrough infections after SARS-CoV2-vaccination - national cohort

Immune responses to COVID-19 vaccines

Impact of COVID-19 on patients with rheumatic diseases

Schlechtere Neutralisation der Delta-Variante unter TNF-alpha Blockern

TNF-Blocker reduzieren Antikörperantwort bei RNA-Impfung

Durchbruchsinfektionen nach SARS-CoV2-Impfung - globales Register

Durchbruchsinfektionen nach SARS-CoV2-Impfung - nationale Kohorte

Womit boostern bei fehlender Serokonversion?

Immunresponser til COVID-19 vaksiner

Skin findings in patients of color with rheumatic disease

New exciting data - dietary supplements with vitamin D and omega-3 fatty acids

CBD - an alternative therapy for chronic pain

Pearls and myths in rheumatology

PROs from a real-world study on etanercept biosimilar - 1 year follow-up

Therapeutic drug monitoring - a randomized controlled trial (NOR-DRUM B)

Neue spannende Daten - Nahrungsergänzung mit Vitamin D und Omega-3-Fettsäuren

Monitorering av legemiddelkonsentrasjoner (Therapeutic drug monitoring, NOR-DRUM B) – en randomiseret kontrollert studie